Literature DB >> 7859590

Insulin secretory response in Japanese type 2 (non-insulin-dependent) diabetic patients.

K Kosaka1, T Kuzuya, R Hagura.   

Abstract

Insulin (immunoreactive insulin, IRI) response during a 100 g oral glucose tolerance test was studied in a large number of patients with definite diabetes, equivocal diabetes, and other pathological states causing glucose intolerance. Definite diabetes was diagnosed in patients with overt fasting hyperglycemia. Once the diagnosis of definite diabetes was made, IRI response remained low after improvement of glucose tolerance. Glucose intolerance caused by other pathological extra-pancreatic conditions was usually accompanied by increased IRI response. IRI response in equivocal diabetes was variable, but almost always decreased in those who developed definite diabetes later. In subjects with a strong family history of type 2 diabetes, the prevalence of a low IRI response was high. In non-diabetic subjects, weight gain caused a marked increase in IRI response and a small increase in blood glucose, while in those who developed diabetes, IRI increased little despite the marked increase in blood glucose. These data suggest that low IRI response is an important feature of type 2 diabetes, perhaps with a hereditary basis in part. It precedes the occurrence of overt hyperglycemia and persists after improvement of glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859590     DOI: 10.1016/0168-8227(94)90235-6

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  4 in total

1.  Reno-protection of G004, a novel anti-diabetic sulfonylurea in db/db mice.

Authors:  Xiaohui Tong; Haijian Ma; Sarah Wambui Amadi; Lingman Ma; Guanzhong Wu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-05-06       Impact factor: 3.000

2.  JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats.

Authors:  T Ohta; N Furukawa; G Komuro; F Yonemori; K Wakitani
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

3.  Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.

Authors:  Akiko Matsuyama-Yokono; Atsuo Tahara; Ryosuke Nakano; Yuka Someya; Masahiko Hayakawa; Masayuki Shibasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-02       Impact factor: 3.000

4.  Molecular scanning of the insulin receptor substrate-1 (IRS-1) gene in Japanese patients with NIDDM: identification of five novel polymorphisms.

Authors:  S Ura; E Araki; H Kishikawa; T Shirotani; M Todaka; S Isami; S Shimoda; R Yoshimura; K Matsuda; S Motoyoshi; N Miyamura; C R Kahn; M Shichiri
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.